Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?
| Autor: | Alejandro Parra Virto, Luis Antonio Alvarez-Sala Walther, Sandra Piqueras Ruiz, Pablo Demelo Rodríguez, Ana Torres do Rego |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Cardiovascular event medicine.medical_specialty Hypercholesterolemia Low density lipoprotein cholesterol Antibodies Monoclonal Humanized Drug Administration Schedule Internal medicine Humans Medicine PCSK9 Inhibitors Aged General Environmental Science Alirocumab Dose-Response Relationship Drug business.industry Anticholesteremic Agents PCSK9 Low cholesterol levels General Engineering Cholesterol LDL Ischemic Attack Transient Cardiology General Earth and Planetary Sciences lipids (amino acids peptides and proteins) business |
| Zdroj: | Clínica e Investigación en Arteriosclerosis (English Edition). 32:29-31 |
| ISSN: | 2529-9123 |
| DOI: | 10.1016/j.artere.2019.04.002 |
| Popis: | Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40–70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipid-lowering treatment. A discussion will be presented on the importance of maintaining low cholesterol levels in order to achieve a greater benefit, according to the latest published clinical studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect